A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1

Chiori Yabuki; Hidetoshi Komatsu; Yoshiyuki Tsujihata; Risa Maeda; Ryo Ito; Kae Matsuda-Nagasumi; Kensuke Sakuma; Kazumasa Miyawaki; Naoya Kikuchi; Koji Takeuchi; Yugo Habata; Masaaki Mori

doi:10.1371/journal.pone.0076280

Loading metrics

Open Access

Peer-reviewed

Research Article

A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1

Chiori Yabuki ,

* E-mail: chiori.yabuki@takeda.com

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Hidetoshi Komatsu,

Affiliation Central Nervous System Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Yoshiyuki Tsujihata,

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Risa Maeda,

Affiliation Central Nervous System Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Ryo Ito,

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Kae Matsuda-Nagasumi,

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Kensuke Sakuma,

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Kazumasa Miyawaki,

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Naoya Kikuchi,

Affiliation Central Nervous System Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Koji Takeuchi,

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Yugo Habata,

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Masaaki Mori

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯

A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1

Chiori Yabuki,
Hidetoshi Komatsu,
Yoshiyuki Tsujihata,
Risa Maeda,
Ryo Ito,
Kae Matsuda-Nagasumi,
Kensuke Sakuma,
Kazumasa Miyawaki,
Naoya Kikuchi,
Koji Takeuchi

Published: October 10, 2013
https://doi.org/10.1371/journal.pone.0076280

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Insulin secretion
Is the Subject Area "Insulin secretion" applicable to this article?

Thanks for your feedback.
Insulin
Is the Subject Area "Insulin" applicable to this article?

Thanks for your feedback.
Glucose
Is the Subject Area "Glucose" applicable to this article?

Thanks for your feedback.
Blood plasma
Is the Subject Area "Blood plasma" applicable to this article?

Thanks for your feedback.
CHO cells
Is the Subject Area "CHO cells" applicable to this article?

Thanks for your feedback.
Diabetes mellitus
Is the Subject Area "Diabetes mellitus" applicable to this article?

Thanks for your feedback.
Cloning
Is the Subject Area "Cloning" applicable to this article?

Thanks for your feedback.
Point mutation
Is the Subject Area "Point mutation" applicable to this article?

Thanks for your feedback.